Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Benefits
May help promote sustained weight loss
May improve blood sugar regulation
May support fat metabolism and energy balance
May contribute to healthier lipid profiles
May help preserve lean muscle mass during weight loss
Dosing
Dose: 500mcg to full dose 10mg
Micro-dose: 500mcg-900mcg once weekly
20 units (500mcg)
24 units (600mcg)
28 units (700mcg)
32 units (800mcg)
36 units (900mcg)
Basic Dosing: 1mg up to 5mg once weekly
40 units = 1mg
80 units = 2mg
120 units = 3mg
160 units = 4mg
200 units = 5mg
How to Use
Duration: Please consult with RN specialist for titration schedule
Administer on the same day each week
Reconstitute: Add 4mL BAC water to the 10mg vial of Retatrutide
Subcutaneous injection
MOA
Multireceptor Incretin Agonism:
Retatrutide is a novel multireceptor agonist that activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Through this dual incretin engagement, Retatrutide modulates key metabolic pathways that regulate appetite, energy expenditure, and glucose homeostasis.
Appetite Suppression and Satiety Signaling:
By stimulating GLP-1 and GIP receptors within the hypothalamus, Retatrutide enhances central satiety signaling and reduces hunger. This neural effect leads to decreased caloric intake and supports sustainable weight reduction.
Glycemic Control and Insulin Regulation:
Retatrutide improves glucose metabolism by stimulating glucose-dependent insulin secretion and suppressing glucagon release. Additionally, it delays gastric emptying, leading to smoother postprandial glucose control and improved glycemic stability.
Insulin Sensitivity and Glucose Uptake:
Dual activation of GLP-1 and GIP receptors enhances peripheral insulin sensitivity and promotes glucose uptake in skeletal muscle and adipose tissue. These combined actions improve metabolic flexibility and reduce insulin resistance.
Hepatic and Lipid Metabolism:
Emerging data indicate that Retatrutide reduces hepatic lipid accumulation, potentially improving non-alcoholic fatty liver disease (NAFLD) outcomes. This hepatoprotective action contributes to overall metabolic and cardiovascular health.
Energy Expenditure and Metabolic Balance:
Beyond appetite and glucose regulation, Retatrutide influences energy expenditure through incretin-mediated pathways that optimize fat utilization and maintain long-term metabolic homeostasis.
More Information
Disclaimer: For Research Purposes Only – All products on this site are for Research and Development use only. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. Celia Health is a supplier of research-use chemicals manufactured in a CGMP facility in the US. Celia Health is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act.
This product requires a prescription. After purchasing, you will receive instructions to schedule and complete your intake exam before your order can be fulfilled. Prescriptions are valid for one calendar year.
Need help finding the right product for you?
Book a consult with a Celia specialist to determine your ideal product protocol.